The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases
| Autor: | Thomas Amatruda, Ananta S Bangdiwala, William Sperduto, Kathryn Beal, John P. Kirkpatrick, Ryan Shanley, Norman Yeh, Emil Lou, Penny K. Sneed, Laurie E. Gaspar, Jason K. Molitoris, Helen A. Shih, Daniel A. Wattson, James B. Yu, David Roberge, Veronica Chiang, Laura Masucci, Wen Jiang, Natalie A. Lockney, Paul D. Brown, Minesh P. Mehta, Steve Braunstein, Paul W. Sperduto |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine Neuroblastoma RAS viral oncogene homolog Oncology Cancer Research Time Factors Gene mutation medicine.disease_cause 0302 clinical medicine 80 and over Molecular Targeted Therapy Melanoma ras Cancer Aged 80 and over Mutation Radiation Brain Neoplasms Statistics Abscopal effect Middle Aged Prognosis Other Physical Sciences Proto-Oncogene Proteins c-kit 030220 oncology & carcinogenesis Female Immunotherapy Proto-Oncogene Proteins B-raf Adult medicine.medical_specialty Clinical Sciences Oncology and Carcinogenesis Antineoplastic Agents Statistics Nonparametric Article 03 medical and health sciences Rare Diseases Clinical Research Internal medicine medicine Humans Nonparametric Radiology Nuclear Medicine and imaging Oncology & Carcinogenesis neoplasms Proportional Hazards Models Retrospective Studies Aged Proportional hazards model business.industry Neurosciences Retrospective cohort study medicine.disease Brain Disorders Brain Cancer Genes ras 030104 developmental biology Genes Linear Models business Brain metastasis |
| Zdroj: | International journal of radiation oncology, biology, physics, vol 98, iss 5 |
| ISSN: | 0360-3016 |
| Popis: | PurposeBrain metastases are a common problem in patients with melanoma, but little is known about the effect of gene mutations on survival in these patients.Methods and materialsWe created a retrospective multi-institutional database of 823 patients with melanoma and brain metastases diagnosed between 2006 and 2015. Clinical parameters, gene mutation status (BRAF, C-KIT, NRAS), and treatment were correlated with survival. Treatment patterns and outcomes were compared with a prior era (1985-2005).ResultsBRAF status was known in 584 of 823 patients (71%). BRAF, NRAS, and C-KIT mutations were present in 51%, 22%, and 11% of tested patients, respectively. The median time from primary diagnosis to brain metastasis was 32months, and overall median survival (MS) from the time of initial treatment of brain metastases was 10months. MS for BRAF-positive and BRAF-negative patients was 13months and 9months, respectively (P=.02). There was no significant difference in MS in patients with or without NRAS or C-KIT mutations. The time from primary diagnosis to brain metastasis did not vary by mutation and was not associated with survival after the diagnosis of brain metastases. MS for the 1985 to 2005 and 2006 to 2015 cohorts was 6.7months and 10.0months, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|